Shots:

• Novartis to acquire Regulus Therapeutics incl. its lead asset, farabursen via its wholly owned subsidiary, which will merge with Regulus upon closing, resulting in Regulus becoming an indirect wholly owned subsidiary of Novartis
• As per the deal, Regulus will get ~$0.8B upfront, with shareholders receiving $7/share in cash, & ~$0.9B upon achievement of a regulatory milestone, payable via CVR of ~$7/share in cash; closing expected in H2’25   
• Farabursen (miR-17 inhibitor) was evaluated in a completed P-Ib multiple-ascending dose trial for autosomal dominant polycystic kidney disease, showing favorable efficacy & safety with impact on urinary polycystin & height-adjusted total kidney volume

Ref: Novartis | Image: Regulus Therapeutics

Related News:- Novartis’ Vanrafia (Atrasentan) Receives the US FDA’s Accelerated Approval for Primary IgA Nephropathy (IgAN)

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com